TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06524544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04701307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT04714372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
Study: NCT06524544

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab Govitecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV
Study: NCT05577455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical prescription before ovulation
Description: Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription before ovulation
Description: Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical prescription after ovulation
Description: Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription after ovulation
Description: Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
Study: NCT05283226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRC-2694-A
Description: 300 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² IV infusion over approximately 3 hours
Study: NCT04789148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
Study: NCT04714372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
Study: NCT04789148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
Study: NCT04714372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
Study: NCT05220657

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal exercise test
Description: A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal exercise test
Description: A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal exercise test
Description: A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
Study: NCT06577935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT05082025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given by IV
Study: NCT05220657

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal exercise test
Description: A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
Study: NCT04641637

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE
Description: Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
Study: NCT05082025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given by IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given by IM
Study: NCT05640544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound and light stimulation in Gamma band
Description: We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients.
Study: NCT05277363

Intervention type: OTHER
Intervention: None (Observational study)
Description: No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
Study: NCT05557682

Intervention type: OTHER
Intervention: composite restorative treatment
Description: Restorative treatment using dental materials
Study: NCT05302050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BT-001
Description: BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control Mobile Application
Description: The app asks patients brief questions about their health but does not include any behavioral therapy.
Study: NCT05527327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traxi® Panniculus Retractor
Description: This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
Study: NCT05708664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction
Description: Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
Study: NCT04894188

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Gosereline 3.6mg sc injection at week 1, week 5, and week 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 MG
Description: Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Study: NCT04766450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
Study: NCT04894188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy
Description: Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical prostatectomy
Description: Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
Study: NCT05064891

Intervention type: PROCEDURE
Intervention: Ultrasound guided injection
Description: Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
Study: NCT04714372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
Study: NCT05465473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
Study: NCT05693584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction
Description: diverting the patient's attention with virtual reality glasses
Study: NCT05742321

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis

Intervention type: OTHER
Intervention: Collection of data
Description: Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
Study: NCT06268665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Given PO
Study: NCT05834153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical muscle stimulation
Description: It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform
Study: NCT06114199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Produce Prescription Program (PPRx) Standard
Description: Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce Prescription Program (PPRx) Standard
Description: Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.